An Open Label, Single-Arm, Multi-center Phase II Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial
Latest Information Update: 07 Jun 2024
At a glance
- Drugs Tislelizumab (Primary) ; Zanidatamab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 10 Mar 2022 New trial record